Abvc Biopharma (ABVC) Income from Non-Controlling Interests (2018 - 2026)
Abvc Biopharma's (ABVC) quarterly Income from Non-Controlling Interests came in at -$129695.0 in Q1 2026, down 1180.79% YoY from $12000.0 in Q1 2025, and up 48.01% on a QoQ basis from -$249469.0 in Q4 2025.
Abvc Biopharma (ABVC) Income from Non-Controlling Interests (2018 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 9 years of Income from Non-Controlling Interests data on file, last reported at -$129695.0 in Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 1180.79% year-over-year to -$129695.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$425295.0 (down 376.26% YoY) and the FY2025 annual result came in at -$468405.0, down 1066.22% from the prior year.
- Income from Non-Controlling Interests grew to -$129695.0 in Q1 2026, from -$249469.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $363036.0 in Q4 2022 to a low of -$316981.0 in Q4 2023.
- A 5-year average of -$38837.2 and a median of -$73535.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2024 — Income from Non-Controlling Interests surged 564.8% — and 2025, when it plunged 2178.91%.
- Tracing ABVC's Income from Non-Controlling Interests over 5 years: stood at $363036.0 in 2022, then sank by 187.31% to -$316981.0 in 2023, then soared by 103.79% to $12000.0 in 2024, then sank by 2178.91% to -$249469.0 in 2025, then jumped by 48.01% to -$129695.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$129695.0 (Q1 2026), -$249469.0 (Q4 2025), and $29680.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | -73,547.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -73,547.00 |
| Mar 31, 2026 | -129,695.00 |
| Dec 31, 2025 | -249,469.00 |
| Sep 30, 2025 | 29,680.00 |
| Jun 30, 2025 | -75,811.00 |
| Mar 31, 2025 | 12,000.00 |
| Dec 31, 2024 | 12,000.00 |
| Sep 30, 2024 | 235,022.00 |
| Jun 30, 2024 | -105,076.00 |
| Mar 31, 2024 | -93,468.00 |
| Dec 31, 2023 | -316,981.00 |
| Sep 30, 2023 | -50,564.00 |
| Jun 30, 2023 | 34,800.00 |
| Mar 31, 2023 | -73,535.00 |
| Dec 31, 2022 | 363,036.00 |
| Sep 30, 2022 | -71,660.00 |
| Jun 30, 2022 | -88,336.00 |
| Mar 31, 2022 | -92,175.00 |
| Dec 31, 2021 | 1.03 Mn |
| Sep 30, 2021 | -79,756.00 |